Kerecis
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kerecis sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Kerecis: 7 sponsored US clinical trials, 2 recruiting.
Kerecis sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Venous Leg, with 2 trials.
Upper-quartile sponsor footprint
Kerecis sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Evaluating the Durability of Closure for Venous Leg Ulcers
NCT06697925
Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers
NCT06693570
AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF
NCT06073301
Prospective Case Registry for Wounds
NCT05898698
Kerecis Case Registry for SurgiBind : Soft Tissue Reinforcement
NCT05898711
Omega3 Wound Fish Skin Graft in the Treatment of DFUs
NCT04133493
Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns
NCT03984331
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 2 |
Therapeutic Areas
Where Kerecis enrollment is open (later-stage tilt)
2 recruiting of 7 indexed (29% open); 1 completed (14%).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Venous Leg (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kerecis: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Kerecis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Kerecis page
7 registered trials is a research-attention snapshot, not an endorsement of Kerecis or any single study.
- 2 of Kerecis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Venous Leg is the condition Kerecis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Venous Leg trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Kerecis pipeline card: 7 registered trials from official public datasets.Report a data error.